Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.

Literature DB >> 15155683

Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.

Luis R Martinez¹, Dariush Moussai, Arturo Casadevall.

Abstract

Cryptococcus neoformans releases capsular polysaccharide in the supernatant of liquid cultures and in tissues. Significantly less glucuronoxylomannan (GXM) was released by C. neoformans in the presence of capsule-binding monoclonal antibody (MAb). MAb-mediated inhibition of GXM release may be another mechanism by which humoral immunity can mediate protection against this pathogen.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15155683 PMCID： PMC415713 DOI： 10.1128/IAI.72.6.3674-3679.2004

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

20 in total

1. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors: A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal: J Infect Dis Date: 1992-06 Impact factor: 5.226

2. Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria.

Authors: A Glatman-Freedman; J M Martin; P F Riska; B R Bloom; A Casadevall
Journal: J Clin Microbiol Date: 1996-11 Impact factor: 5.948

3. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors: D L Goldman; S C Lee; A Casadevall
Journal: Infect Immun Date: 1995-09 Impact factor: 3.441

4. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors: A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

5. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors: J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

Review 6. Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors: R Cherniak; J B Sundstrom
Journal: Infect Immun Date: 1994-05 Impact factor: 3.441

7. Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors: A Casadevall; J Mukherjee; M D Scharff
Journal: J Immunol Methods Date: 1992-09-18 Impact factor: 2.303

8. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.

Authors: A Casadevall; M D Scharff
Journal: J Exp Med Date: 1991-07-01 Impact factor: 14.307

9. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.

Authors: G Nussbaum; W Cleare; A Casadevall; M D Scharff; P Valadon
Journal: J Exp Med Date: 1997-02-17 Impact factor: 14.307

10. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.

Authors: J Mukherjee; G Nussbaum; M D Scharff; A Casadevall
Journal: J Exp Med Date: 1995-01-01 Impact factor: 14.307

26 in total

1. Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors: Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal: Infect Immun Date: 2019-01-24 Impact factor: 3.441

2. Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors: Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal: Eukaryot Cell Date: 2006-11-17

3. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.

Authors: Erin E McClelland; André M Nicola; Rafael Prados-Rosales; Arturo Casadevall
Journal: J Clin Invest Date: 2010-03-24 Impact factor: 14.808

4. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation.

Authors: Emma J Robertson; Arturo Casadevall
Journal: Appl Environ Microbiol Date: 2009-02-27 Impact factor: 4.792

Review 5. Immune response and immunotherapy to Cryptococcus infections.

Authors: Qing Zhou; William J Murphy
Journal: Immunol Res Date: 2006 Impact factor: 2.829

6. Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.

Authors: Hiu Ham Lee; Jaclyn Del Pozzo; Sergio A Salamanca; Hazael Hernandez; Luis R Martinez
Journal: Fungal Genet Biol Date: 2019-07-26 Impact factor: 3.495

7. A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.

Authors: Anthony Bowen; Maggie P Wear; Radames J B Cordero; Stefan Oscarson; Arturo Casadevall
Journal: J Biol Chem Date: 2016-11-21 Impact factor: 5.157